Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen
Clinical trial NCT04549025 · TERMINATED
Trial details
- NCT number
- NCT04549025
- Sponsor
- Jounce Therapeutics, Inc.
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-10-19
- Primary completion
- 2024-04-25
- Enrollment
- 69
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.